摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl-(3R,5S,6E)-7-[6,7,8-trifluoro-4-(4-fluorophenylthio)quinoline-3-yl]-3,5-dihydroxyhept-6-enoate | 1352429-10-7

中文名称
——
中文别名
——
英文名称
tert-butyl-(3R,5S,6E)-7-[6,7,8-trifluoro-4-(4-fluorophenylthio)quinoline-3-yl]-3,5-dihydroxyhept-6-enoate
英文别名
——
tert-butyl-(3R,5S,6E)-7-[6,7,8-trifluoro-4-(4-fluorophenylthio)quinoline-3-yl]-3,5-dihydroxyhept-6-enoate化学式
CAS
1352429-10-7
化学式
C26H25F4NO4S
mdl
——
分子量
523.548
InChiKey
KSSFPCUJERRFJJ-MWRSBEEJSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.8
  • 重原子数:
    36.0
  • 可旋转键数:
    8.0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.31
  • 拓扑面积:
    79.65
  • 氢给体数:
    2.0
  • 氢受体数:
    6.0

反应信息

  • 作为反应物:
    描述:
    tert-butyl-(3R,5S,6E)-7-[6,7,8-trifluoro-4-(4-fluorophenylthio)quinoline-3-yl]-3,5-dihydroxyhept-6-enoate 、 sodium hydroxide 作用下, 以 四氢呋喃 为溶剂, 以244.1 g的产率得到(3R,5S,6E)-7-[4-(4-fluorophenylthio)-6,7,8-trifluoroquinolin-3-yl]-3,5-dihydroxy-6-heptenoic acid
    参考文献:
    名称:
    Development of a Practical and Efficient Synthesis of SIPI-4884, a HMG CoA Reductase Inhibitor for the Treatment of Hypercholesterolemia
    摘要:
    An improved process of the novel HMG CoA reductase inhibitor SIPI-4884 has been developed for early preclinical pharmacology and safety studies, and it was made up with an efficient nine-step and scalable process. Significant improvements in the nucleophilic substitution, reduction, Wittig-Horner reaction, and preparation of calcium salt were demonstrated. The overall yield was improved to 17.2%.
    DOI:
    10.1021/op400060z
  • 作为产物:
    描述:
    4-(4-fluorophenylthio)-6,7,8-trifluoroquinoline-3-methanol 在 2,2,6,6-四甲基哌啶盐酸正丁基锂三溴化磷 作用下, 以 四氢呋喃2-甲基四氢呋喃正己烷二氯甲烷甲苯 为溶剂, 反应 8.0h, 生成 tert-butyl-(3R,5S,6E)-7-[6,7,8-trifluoro-4-(4-fluorophenylthio)quinoline-3-yl]-3,5-dihydroxyhept-6-enoate
    参考文献:
    名称:
    Development of a Practical and Efficient Synthesis of SIPI-4884, a HMG CoA Reductase Inhibitor for the Treatment of Hypercholesterolemia
    摘要:
    An improved process of the novel HMG CoA reductase inhibitor SIPI-4884 has been developed for early preclinical pharmacology and safety studies, and it was made up with an efficient nine-step and scalable process. Significant improvements in the nucleophilic substitution, reduction, Wittig-Horner reaction, and preparation of calcium salt were demonstrated. The overall yield was improved to 17.2%.
    DOI:
    10.1021/op400060z
点击查看最新优质反应信息